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Abstract
Many mutations in cancer are of unknown functional significance. Standard methods use statistically significant
recurrence of mutations in tumor samples as an indicator of functional impact. We extend such analyses into the
long tail of rare mutations by considering recurrence of mutations in clusters of spatially close residues in protein
structures. Analyzing 10,000 tumor exomes, we identify more than 3000 rarely mutated residues in proteins as
potentially functional and experimentally validate several in RAC1 and MAP2K1. These potential driver mutations
(web resources: 3dhotspots.org and cBioPortal.org) can extend the scope of genomically informed clinical trials
and of personalized choice of therapy.
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Background
Recent large-scale sequencing efforts such as The Can-
cer Genome Atlas (TCGA) have revealed a complex
landscape of somatic mutations in various cancer types
[1]. While the data generated have provided a more
complete picture of the genomic aberrations in cancer
cells, the interpretation of individual mutations can be
difficult. One of the key challenges is distinguishing the
few mutations that functionally contribute to oncogen-
esis (“drivers”) from the many biologically neutral muta-
tions (“passengers”) [2].
Several methods are currently being used to identify
driver genes based on the frequency of mutations ob-
served in a gene across a set of tumors, e.g., MutSig [3]
and MuSiC [4]. These methods have two limitations: (1)
their unit of analysis is a gene and they do not distin-
guish individual driver mutations from passengers in a
given gene, and (2) they are not able to detect functional
mutations in infrequently mutated genes, often referred
to as the “long tail” of the frequency distribution of som-
atic mutations in cancer [5].
To move beyond a gene-level definition of drivers and
to identify position- and allele-specific driver mutations,
we previously developed a statistical method that identi-
fied hundreds of single-residue mutational hotspots
across various cancer types [6]. However, the vast major-
ity of somatic mutations identified in tumors occur in-
frequently and most are likely non-functional passenger
events. But a small subset of these rare mutations repre-
sent functional driver events, and these would be over-
looked by methods that rely exclusively on mutation
frequency at individual amino acid positions. It is there-
fore important to develop more refined methods that at
the genome scale identify infrequent mutations that are
likely functional. Though individually rare, these long-
tail mutations are present in a significant fraction of
tumors and are likely key molecular events and thus
potential drug targets [5]. Several methods exist that
identify driver genes or mutations in the long tail by
incorporating protein-level annotation, such as local
positional clustering [7], phosphorylation sites [8], and
paralogous protein domains [9].
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Recently, three-dimensional (3D) protein structures
have also been used to identify driver genes and mutations
in cancer and other diseases. For example, Dixit et al. [10]
studied cancer mutations in 3D structures of protein ki-
nases. Wang et al. [11] generated a structurally solved in-
teractome to study genetic diseases. Porta-Pardo et al. [12]
and Engin et al. [13] used 3D structures to detect protein-
protein interaction interfaces that are enriched with
cancer mutations. Clustering of mutations in protein
structures (CLUMPS) [14] used 3D clustering of muta-
tions to detect cancer genes and also studied enrichment
of mutations in protein-protein interaction interfaces.
StructMAn [15] annotated the amino acid variations of
single-nucleotide polymorphisms (SNPs) in the context of
3D structures. SpacePAC [16], Mutation3D [17], Hot-
MAPS [18], and Hotspot3D [19] used 3D structures to
identify mutational clusters in cancer. These efforts have
generated interesting sets of candidate functional muta-
tions and illustrate that many rare driver mutations are
functionally, and potentially clinically, relevant.
Here, we describe a novel method that identifies muta-
tional 3D clusters, i.e., missense (amino-acid-changing)
mutations that cluster together in 3D proximity in pro-
tein structures above a random background, with a focus
on identifying rare mutations. In this largest 3D cluster
analysis of whole exome or genome sequencing data in
cancer to date, we analyzed more than one million som-
atic missense mutations in 11,119 human tumors across
32,445 protein structures from 7390 genes. The analysis
identified potential driver mutations, the majority of
which are rare mutations (occurring in <0.1% of patients
in the dataset), in 3405 residues clustering in the protein
structures of 503 genes (Fig. 1). Many of these 3D clus-
ters were identified in well-characterized cancer genes,
such as KRAS, BRAF, and TP53, and include known
oncogenic recurrent alleles (e.g., KRAS G12D) as well as
rare long-tail alleles (e.g., KRAS D33E, which has re-
cently been experimentally validated [20]). We were able
to identify new potential driver genes as well as novel
candidate driver mutations in clinically actionable cancer
Fig. 1 Mutational 3D cluster analysis method and related resources. a Process of going beyond single-residue hotspots by considering occurrence
in 3D clusters. The colors of different types of mutated residues in 3D clusters are defined in the bottom panel and used throughout the manuscript.
b Mutations in 3D clusters can be explored via the web resource http://3dhotspots.org. The results are also made available via a web API service for
use by other bioinformatics tools, and mutations viewed in the cBioPortal for Cancer Genomics are annotated if they are part of an identified 3D
cluster. The identified 3D clusters are likely to change as the cancer genomics and 3D structure databases grow
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genes that were not detected by our mutational single-
residue hotspot detection method [6] and other 3D clus-
ter detection methods [17–19]. We experimentally
tested the activating potential of rare mutations identi-
fied in 3D clusters in the MAP2K1 and RAC1 proteins,
enlarging the number of biologically and potentially clin-
ically significant alleles in these two critical effectors of
activated signaling pathways in cancer. To facilitate fur-
ther biological and clinical validation, we have made the
catalog of 3D cluster mutations available through an
interactive web resource (http://3dhotspots.org) and in
the widely used cBioPortal for Cancer Genomics (http://
cbioportal.org) [21, 22] (Fig. 1b).
Methods
Mutational data collection and processing
Mutational data were obtained from publicly available
sources including The Cancer Genome Atlas (TCGA),
the International Cancer Genome Consortium (ICGC),
and published studies from the literature [21, 22]. Muta-
tions were processed as described previously [6]. Briefly,
genomic coordinates of variants were standardized to
the human reference assembly GRCh37. Genomic coor-
dinates from previous assemblies were converted to
GRCh37 via LiftOver (https://genome.ucsc.edu/cgi-bin/
hgLiftOver). Mutations were annotated based on
Ensembl release 75, and the mutational effect was anno-
tated on canonical isoforms per gene defined by UniProt
canonical sequences (http://www.uniprot.org/help/cano
nical_and_isoforms) using Variant Effect Predictor (VEP)
version 77 (http://ensembl.org/info/docs/tools/vep/) and
vcf2maf version 1.5 (https://github.com/mskcc/vcf2maf).
To remove potential germline variants misreported as
somatic mutations, we excluded mutations found in
both the 1000 Genomes Project and the National Heart,
Lung, and Blood Institute (NHLBI) Exome Sequencing
Project, as well as those identified in the 1000 Genomes
Project in two or more samples. Furthermore, we re-
moved mutations in genes whose RNA expression was
less than 0.1 transcript per million (TPM) in 90% or
more of the tumors of that type based on TCGA RNA
expression data. For samples whose cancer types lack
RNA expression data, genes were removed if more than
95% of all tumors in our dataset had RNA expression of
TPM less than 0.1. Complete details on data processing
were documented in Chang et al. 2016 [6].
Protein 3D structure data collection and processing
Protein structures were downloaded from the Research
Collaboratory for Structural Bioinformatics (RCSB) Pro-
tein Data Bank (PDB, http://www.rcsb.org/) [23]. Align-
ments of protein sequences from UniProt [24] to PDB
were retrieved from MutationAssessor [25] and the
Structure Integration with Function, Taxonomy and
Sequences (SIFTS) resource [26]. Only alignments with
a sequence identity of 90% or above were included. For
each structure chain, a contact map of residues was cal-
culated. Two residues are considered in contact if any
pair of their atoms is within 5 angstroms (Å), as calcu-
lated by BioJava Structure Module [27]. A 3D cluster is
defined by a central residue and its contacting neighbor
residues (Additional file 1: Figure S1a). All residues are
used in turn as centers of clusters. The test of statistical
significance (described in the following subsection) is
applied separately to each cluster in turn. Clusters are
not merged, so each residue can be in more than one
cluster, even after filtering for statistical significance of
the clusters.
Identifying significantly mutated 3D clusters
A 3D cluster was identified as significantly mutated if its
member residues were more frequently mutated in the
set of samples than expected by chance. Mutations were
mapped to the aligned PDB sequences and structures
(Additional file 1: Figure S1a), and the total number of
mutations across all samples was calculated within each
3D cluster. To determine whether the residues in a 3D
cluster in a particular structure were more frequently
mutated than expected by chance, a permutation-based
test was performed by generating 105 decoy mutational
patterns on the aligned region of the protein structure.
A decoy pattern was generated by randomly shuffling
the residue indices (positions in the sequence), with their
associated mutation count, on the structure (Additional
file 1: Figure S1b, c). For each decoy mutational pattern,
the number of mutations in each cluster was calculated
as above. For a given 3D cluster in question, the p value
was calculated as the fraction of decoys for which the
number of mutations (based on the decoy data) in any
cluster was equal to or larger than the number of muta-
tions (based on the real data) in the 3D cluster in ques-
tion. When shuffling the mutations, the mutation count
in each residue was maintained, except that we set the
maximum number of mutations in one residue in the
decoy to the largest number of mutations in the assessed
3D cluster with the intent of ensuring detection of less
frequently mutated 3D clusters within a gene with one
or a few dominant single-residue hotspots (such as
BRAF V600) (Additional file 1: Figure S1b, c). In the rest
of the manuscript, we use the term ”3D cluster” as a
short alias for ”significantly mutated 3D cluster.”
Experimental assays to test identified MAP2K1/MEK1
mutations
Cell line and culture
Human embryonic kidney HEK-293H cells (Invitrogen)
were maintained in Dulbecco's Modified Eagle's (DME)-
HG medium with 10% fetal bovine serum (FBS),
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supplemented with 2 mM glutamine, and 50 units/ml
each of penicillin and streptomycin.
Transfections
MAP2K1 mutant constructs were generated from the
MEK1-GFP plasmid (#14746, Addgene, Cambridge, MA,
USA) using the QuikChange II XL Site-Directed Muta-
genesis Kit (Stratagene) as recommended. All mutant
plasmids were verified by Sanger sequencing. HEK-293H
cells were seeded for 70–90% confluency at the time of
transfection, then transiently transfected with the wild-
type or mutant MEK1-GFP plasmid using Lipofecta-
mine® 2000 Transfection Reagent (Invitrogen). Plasmid
transfection levels were standardized according to green
fluorescent protein (GFP) expression. Cells were col-
lected 24 hours post-transfection.
Western blot analysis
Cells were lysed in 1% NP-40 buffer with protease and
phosphatase inhibitors, then processed for immunoblot-
ting as previously described [28]. Rabbit polyclonal anti-
bodies recognizing MEK1/2, phosphorylated ERK1/2
(Thr202/Tyr204), and ERK1/2 were obtained from Cell
Signaling, Danvers, MA, USA. Rabbit monoclonal anti-
bodies recognizing GFP and GAPDH were obtained
from Cell Signaling. After incubation with horseradish
peroxidase-conjugated secondary antibody, proteins
were detected by chemiluminescence (SuperSignal West
Dura Chemiluminescent Substrate, Thermo Scientific)
and visualized using the Fuji LAS-4000 imager (GE Life
Sciences, Pittsburgh, PA, USA).
Drug experiments
HEK-293H cells were transfected with MEK1 wild-type
or mutant GFP-tagged plasmid. At 24 hours, cells were
treated with 100 nM trametinib (Selleck Chemicals,
Houston, TX, USA) and collected after 2 hours. Control
cells were treated with dimethyl sulfoxide (DMSO). Cells
were lysed for protein and immunoblotted as referenced
above.
Experimental assay to test identified RAC1 mutations
Cell line and culture
Early-passage HEK-293 T cells, acquired from American
Type Culture Collection (ATCC), Manassas, VA, USA
and authenticated as mycoplasma free, were cultured at
37 °C in 5% CO2 in DMEM supplemented with 10%
FBS.
Transfections
RAC1 mutation validation was performed similarly to
what was previously described [6]. DNA coding se-
quences for mutant RAC1 constructs were generated via
site-directed mutagenesis (Genewiz, South Plainfield, NJ,
USA). All mutant plasmids were verified by Sanger se-
quencing. RAC1 constructs contained an N-terminal
3xFLAG epitope tag and were subcloned into a pcDNA3
mammalian expression vector (Life Technologies, Grand
Island, NY, USA). The expression constructs were trans-
fected into these cells using Lipofectamine 2000 (Life
Technologies).
Western blot analysis
Cells were harvested 72 hours after transfection. GTP-
bound RAC1 (active RAC1) was isolated via immuno-
precipitation using recombinant p21-binding domain
(PBD) of PAK1 (PAK1-PBD; Active RAC1 Detection Kit,
Cat. #8815, Cell Signaling Technology), according to the
manufacturer's instructions. Total RAC1 was detected
using kit-provided RAC1 primary antibody.
Results
A catalog of mutational clusters in protein structures
We have curated a comprehensive dataset of somatic
mutations, consisting of sequenced exomes and genomes
of 11,119 human tumors spanning 41 cancer types. The
dataset contained 1,182,802 somatic missense mutations
occurring in 1,025,590 residues in 18,100 genes, out of
which the protein sequences of 7390 genes were aligned
to 32,445 protein 3D structures. Most (908,009) of these
residues were mutated only once in the 11,119 samples
(Fig. 2a); i.e., most somatic mutations found in cancer
are extremely rare. Most of these rare mutations are
likely passenger mutations, but some may be
unrecognized drivers [20]. Indeed, we found that a small
fraction of rarely mutated residues (e.g., mutated in
three or fewer samples) are members of recurrently mu-
tated clusters in 3D structures (Fig. 2a) and thus prob-
ably are functional drivers.
In total, we identified 943 unique mutational clusters
(clusters with the same set of residues in amino acid
sequence were counted as one unique cluster) that
were statistically significant in 2382 protein structures
(Additional file 2: Table S1). These 3D clusters
encompassed 3404 residues in 503 genes (Additional
file 3: Table S2). TP53 contained the largest number
of residues in 3D clusters (66 residues), followed by
PTEN (48), SMAD4 (33), and KEAP1 (26) (Fig. 2b,
Additional file 4: Table S3). TP53 mutations in 3D
clusters were also the most prevalent across all cancer
types (in 1914 samples, 17%), followed by KRAS (8%),
BRAF (6%), and PIK3CA (4%), underscoring the roles
of these well-characterized cancer genes in oncogen-
esis (Fig. 2c, Additional file 5: Table S4).
We classified the mutated residues in a 3D cluster into
three categories (Figs. 1 and 2d, Additional file 3: Table S2)
depending on whether the cluster contains single-residue
hotspots identified by [6]: (1) 103 residues in single-residue
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hotspots, (2) 263 rarely mutated residues that were clus-
tered in 3D with a single-residue hotspot, and (3) 3038
rarely mutated residues that were clustered in 3D only with
other rarely mutated residues. If a rarely mutated residue
belonged to category 2 in one cluster and category 3 in
another, the residue was classified as category 2. There
were 367 hotspots identified by [6] that were not detected
in 3D clusters (Fig. 2d), either because they were not part
of a significant cluster with other mutated residues or
because there was no 3D structure available for the protein
or protein region.
Notably, in 5038 samples (45%), prior frequency-based
hotspot analysis failed to identify single-residue hotspot
driver mutations. By incorporating protein structure
data, rare mutations present in 3D clusters were identi-
fied in 865 of these samples (17% of the samples without
single-residue hotspot driver mutations, or 8% of all
samples) (Fig. 2e). As an example, 141 (15%) of 961 lung
tumors (lung adenocarcinoma, lung squamous cell
carcinoma, and small-cell lung cancer) with no single-
residue hotspot mutations carried a rare mutation in a
3D cluster. Assuming the diseases of these patients were
genetically driven, these 3D cluster mutations were pos-
sibly driver events (Fig. 2e).
3D cluster analysis identified rare missense driver
mutations in tumor suppressor genes
While tumor suppressor genes are often inactivated by
truncating (e.g., nonsense and frameshift) mutations,
their function may also be disrupted by missense mu-
tations in critical regions. These missense mutations,
unlike hotspot mutations in oncogenes, often are not
recurrent at individual positions, but instead their re-
currence may only be evident in mutational clusters.
By using protein structures, we identified potentially
inactivating mutational clusters in critical regions of





Fig. 2 3D cluster analysis reveals numerous potentially functional rare mutations. a 3D cluster analysis identified a large number of statistically
significant, yet rarely mutated residues (mutated one to three times in our dataset). The residues were binned by the number of mutations in
each residue. The mutation counts for the single-residue hotspots also contain a small fraction of silent, nonsense, and splice-site mutations identified
by Chang et al. 2016 [6]. b Genes with the highest number of residues in 3D clusters. c Genes with the highest frequency of tumor samples with
mutations clustered in 3D structures across all cancer types. d Per-residue comparison of significance as in single-residue hotspot (vertical
axis) and 3D cluster (horizontal axis). Many residues were hotspots as well as parts of 3D clusters (upper right quadrant), but some were
detected only as part of 3D clusters (bottom right quadrant). e Number of residues (upper panel) and percentage of samples (bottom
panel) with hotspots and 3D clusters per cancer type (see full cancer type names in the Abbreviations section). The category of a sample
was assigned based on the lowest category if it had mutations that belonged to different categories
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PTEN is one of the most frequently mutated tumor
suppressors with mutations occurring in various cancers.
In PTEN, we identified 15 3D clusters that included 48
residues (2 single-residue hotspots, 46 rarely mutated
residues) (Fig. 3a, Additional file 3: Table S2). All these
clusters reside in the flanking regions surrounding the
phosphatase catalytic core motif (Fig. 3a), a region that
is necessary for PTEN activity [29].
CDH1 encodes E-cadherin, a transmembrane glyco-
protein mainly expressed in epithelial cells. Germline
mutations in CDH1 are associated with an increased risk
of gastric and breast cancer [30], and CDH1 somatic
inactivation via epigenetic silencing or truncating muta-
tions is common in both cancer types. We identified 11
3D cluster residues (all rarely mutated residues; muta-
tion frequency 0.01–0.06% individually) in CDH1
(Fig. 3b, Additional file 3: Table S2). Out of the 19 sam-
ples with these 3D cluster mutations, 11 were gastric
tumors. Although distant in amino acid position (be-
tween the 165th and 291st residues), in 3D space, all of
these residues surround the junction between the first
and second extracellular cadherin domains in the 3D
structure (Fig. 3b). Mutations in these residues are likely
to perturb functionally essential calcium-binding sites in
the junction region [31] and hence are likely inactivating
and potentially oncogenic.
KEAP1 is a substrate adapter protein for the E3 ubi-
quitin ligase that targets NFE2L2 (NRF2) for ubiquitina-
tion and subsequent degradation. Loss-of-function
mutations in key KEAP1 residues result in accumulation
of NRF2 in the nucleus and contribute to chemoresis-
tance in vitro [32]. We identified 26 3D cluster
residues (all rarely mutated residues; mutation fre-
quency 0.01–0.03% individually) in KEAP1 (Fig. 3c,
Additional file 3: Table S2). These mutations were
localized to the interaction domain of KEAP1, sug-
gesting that they likely disrupt NRF2 binding (Fig. 3c).
Notably, out of the 36 samples with these mutations,
18 were lung adenocarcinomas, 6 of which lacked
hotspot mutations.
Functional validation of rare mutations identified in 3D
clusters
Identifying mutations in genes for which targeted ther-
apies exist or are being developed, regardless of their in-
dividual frequency in the population, is critical for the
effective practice of precision oncology. Our analysis
identified 3D clusters in several genes for which selective
inhibitors are either used as part of standard clinical
management or are being actively tested in clinical trials,
including EGFR, KIT, MTOR, PIK3CA, MAPK1, and
FGFR3 (Table 1). The 3D clusters within these genes
contained known activating single-residue hotspot muta-
tions as well as rare candidate driver mutations. While
the function of most of these rare mutations is un-
known, a subset has been functionally characterized in
prior studies. For example, EGFR T263P has been re-
ported to induce oncogenic EGFR activation [33], and
recently, many of the rare mutations in MTOR present
within 3D clusters (A1459P, L1460P, Y1463S, T1977R,
Fig. 3 Examples of mutational 3D clusters in tumor suppressor genes. a Residues in 3D clusters in PTEN highlighted in the protein sequence (top)
and a protein structure (bottom). The 3D cluster residues surround the catalytic site. b Residues in 3D clusters in CDH1 (E-cadherin) highlighted in
the protein sequence (top) and a protein structure (bottom). The 3D cluster mutations are likely to disrupt the critical calcium-binding site (calcium
atoms in red). c 3D clusters in KEAP1 in the protein sequence (top) and a protein structure (bottom). Most of the 3D cluster mutations are in the
NRF2-binding region (NRF2 peptide in purple)
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and V2006I/L) (Table 1) have been shown to induce
increased mTORC1/2 pathway activity [34].
To confirm that the method could identify functional
driver mutations that would not have been nominated
by previously reported frequency-based methods, we
functionally tested several rare mutations identified in
3D clusters in the MAP2K1 and RAC1 genes. Compo-
nents of the MAPK pathway are among the most com-
monly altered genes in human cancer. Our method
revealed 3D clusters in all three RAS proteins (K/N/H-
RAS), RAC1, BRAF, MAP2K1, and MAPK1 in a variety
of cancer types. MEK1, which is encoded by the
MAP2K1 gene, is a dual specificity kinase that phosphor-
ylates ERK to propagate MAPK signaling transduction.
Activating mutations in MAP2K1 have been shown to
result in constitutive MAPK pathway activity and to
confer resistance to RAF inhibition and MEK inhibitor
sensitivity [35, 36].
We identified a 3D cluster (p = 0.03) in MAP2K1 that
included seven mutated residues (R49, A52, F53, Q56,
K57, G128, and Y130). Two of these residues (F53 and
K57) are single-residue hotspots [6] and are shown to
induce constitutive ERK pathway activation [37]. The
other five were rarely mutated (mutation frequency of
0.01–0.03% individually) (Fig. 4a). All seven of these
mutated residues reside in the shared interface between
helix A and the kinase domain (Fig. 4b). As helix A has
previously been shown to negatively regulate MEK1 kin-
ase activity by interacting with the kinase domain [38],
mutations that disrupt this interaction may result in
constitutive ERK pathway activation. We thus experi-
mentally assessed the ability of the mutations in this 3D
cluster to induce ERK1/2 phosphorylation in a cellular
model. We found that expression of five of the mutated
proteins, including G128D, Y130C, and also the previ-
ously characterized F53L, Q56P, and K57N mutations
[37], induced downstream MAPK signaling as assessed
by increased expression of phosphorylated ERK (Fig. 4c).
To test whether the Y130C variant protein that is not in
a single-residue hotspot, but was nominated by 3D
cluster analysis, is sensitive to MEK inhibition, we
treated HEK-293 T cells expressing the Y130C mutant,
or as a positive control the Q56P mutant, with trameti-
nib, an FDA-approved MEK inhibitor. Trametinib treat-
ment resulted in significant down-regulation of MAPK
pathway activity (Fig. 4d). As durable responses to MEK
inhibitors have been reported in patients whose tumors
have an activating mutation in MAP2K1 [36], this
example highlights the potential translational impact of
3D cluster analysis.
RAC1 is a Rho family small GTPase that has been
recently implicated to confer resistance to RAF inhib-
ition in vitro and may underlie early resistance in
patients [39]. Recently, two oncogenic single-residue
hotspots in RAC1 were identified, P29 and A159,
both of which activate RAC1 in vitro [6]. We identi-
fied a statistically significant 3D cluster of four resi-
dues (p = 0.009) in RAC1, which, in addition to P29
and A159, includes novel rare mutations at amino
acids G15 and C18 (mutation frequency of 0.01–
0.02%, respectively) (Fig. 4e and f ). To confirm that
these mutations activate RAC1, we utilized a PAK1-
pulldown assay to quantify activated RAC1 expression
in cells expressing mutant and wild-type RAC1 pro-
tein. We found that, compared to wild-type RAC1,
both the G15S and C18Y RAC1 mutants resulted in
elevated active RAC1 expression (Fig. 4 g). These re-
sults expand the number of experimentally validated
activating alleles in RAC1, suggesting that RAC1
G15S and C18Y mutations in this 3D cluster may
possess similar biological consequences to those of
the previously characterized RAC1 hotspot mutations.
In-depth functional testing of mutations in the more
than 3000 potential driver alleles in 503 genes identified
by our 3D cluster method could not be feasibly per-
formed by a single laboratory. Therefore, to facilitate this
effort, we have made publically available all the muta-
tions revealed by this analysis via an interactive website,
http://3dhotspots.org. On the website, users can view
and search for mutations in 3D clusters, explore details
Table 1 Example 3D clusters with potential functional targets
Gene PDB ID: chain Position (number of mutated samples) p Cancer types (number of mutated samples)*
EGFR 1IVO:B R252(8) F254(1) D256(2) K261(1) T263(2) C264(1) A289(28) 0.016 GBM(30) LGG(8) Stomach ADCA(2) Other(3)
EGFR 2JIU:B V769(1) R831(2) R832(2) L833(2) L858(30) L861(7) H893(1) 0.025 Lung ADCA(39) Lung SCC(2) CRC(2) Other(2)
KIT 4HVS:A W557(1) V559(3) V560(1) L576(2) 0.085 Melanoma(6) Stomach ADCA(1)
MTOR 4JT5:B A1459(1) L1460(2) V1461(1) Y1463(1) K1465(1) M1467(1)
R1480(2) C1483(5)
0.035 ccRCC(7) BRCA(1) CRC(1) Other(5)
MTOR 4JSN:A A1971(3) I1973(2) Y1974(1) T1977(3) M1998(1) V2006(2) 0.047 ccRCC(4) CLL(2) Endometrial CA(2) Other(4)
PIK3CA 2v1y_A R38(14) E39(5) R88(40) C90(4) R93(15) 0.014 Endometrial CA(27) CRC(19) Other(32)
MAPK1 4FV5:A E81(2) R135(1) G136(1) D321(3) E322(15) 0.014 Cervical SCC(9) HNC(9) BRCA(1) Other(3)
FGFR3 1RY7:B R248(9) S249(18) P250(1) D280(2) 0.050 Bladder CA(17) HNC(6) Lung SCC(3) Other(4)
*Full cancer type names are listed in the Abbreviations section
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about each mutation and cluster, and visualize the muta-
tions in interactive 3D structures (Fig. 1b). Mutations
that are part of a 3D cluster will also be highlighted in
all mutation tables in the cBioPortal for Cancer Genom-
ics, with a link to http://3dhotspots.org (Fig. 1b). We
intend to keep the site up to date as additional muta-
tional and protein structure data are generated. We an-
ticipate that these data will provide a basis for detailed
biological studies by investigators with gene-specific
expertise and could also be used to guide clinical trial
eligibility for molecularly driven studies in precision
medicine.
Comparison of 3D hotspot detection tools
Alternative, independently developed 3D cluster detec-
tion methods have also identified recurrent mutations
that cluster in 3D structures. All of these methods evalu-






Fig. 4 Experimental validation of functional impact of mutations in 3D clusters in MAP2K1 and RAC1. a Seven residues in a 3D cluster in MAP2K1,
in the context of the domain structure of the protein. Notation as in Fig. 1: each circle is an occurrence in a sample; connecting lines (bottom)
indicate cluster membership, i.e., statistically significant proximity in 3D in the protein structure. b The same cluster of mutated residues in the
3D structure of MAP2K1. The purple helix is known to negatively regulate the kinase activity of MAP2K1/MEK1. c Functional characterization of
MAP2K1/MEK1 mutants in HEK-293H cells. Expression of G128D and Y130C (as well as the previously characterized F53L, Q56P, and K57N) mutants
each resulted in increased expression of phosphorylated ERK compared to wild-type MAP2K1 — but not the cluster member A52V. d ERK
phosphorylation was inhibited by trametinib in cells expressing the Q56P or Y130C MAP2K1 mutations in HEK-293H cells. e The four residues (two single-
residue hotspots: P29 and A159, and two rarely mutated residues: G15 and C18) in the identified 3D cluster in RAC1 in the linear domain structure of the
protein. f The same cluster in the 3D structure of RAC1. g Western blot analysis of RAC1 activation (GTP-bound RAC1 levels) by PAK1 pulldown (left) and
of total RAC1 levels (right) in HEK-293 T cells. The RAC1 3D cluster mutations G15S and C18Y, as well as the previously characterized P29S and A159V,
were associated with significant RAC1 activation, as compared to wild-type RAC1
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background, counting occurrences of a mutation in any
member of a 3D cluster in a set of tumor samples. How-
ever, the methods differ in detail, e.g., in the tumor sets
analyzed, the definition of 3D clusters, and the statistical
test applied, and so they produce different lists of candi-
date functional mutations. For example, Mutation3D
identified 399 mutated residues in 75 genes as likely
functional [17], HotMAPS identified 398 mutated resi-
dues in 91 genes [18], and Hotspot3D identified 14,929
mutated residues in 2466 genes [19], whereas our
method identified 3404 mutated residues in 503 genes
(Additional file 6: Table S5 and Additional file 7: Figure
S2). Somewhat surprisingly, only 15 mutated residues
were identified by all four methods, all of which were
also previously identified as single-residue hotspots [6].
Of the 3404 mutated residues, 2908 detected by our
method were not identified by any of the other three
methods, including MAP2K1 Q56 and K57, which we
experimentally validated. Comparison to a recent experi-
mental in vivo screening study of rare mutations by Kim
et al. [20] also confirmed that the four methods have dif-
ferent coverage and power to detect rare driver muta-
tions and therefore provide complementary datasets of
candidate functional mutations (Additional file 8: Table
S6). For example, the method described here was able to
detect the KRAS D33E and SPOP K134N mutations that
were validated as functional by Kim et al. [20], but the
other three methods did not detect these mutations as
statistically significant.
Discussion
Tremendous effort has been invested in the discovery of
therapeutic agents to suppress oncogenic signaling.
These efforts have resulted in several FDA-approved
agents that target a variety of genes and pathways in sev-
eral different cancer types. For instance, vemurafenib, a
selective inhibitor of V600E/K mutant BRAF, was first
approved in metastatic melanoma, a cancer in which ap-
proximately 50% of tumors harbor a BRAF V600E/K
mutation [40]. Vemurafenib has since shown activity in
a wide spectrum of malignancies that share this action-
able mutation [41], suggesting that molecular bio-
markers can be predictive of drug response across
cancer types. However, effective development and use of
targeted therapies necessitate identification of “driver”
mutations among the far more prevalent passenger mu-
tations in patient genomes. Many of these mutations can
be identified by their recurrence in a single position, but
others are less common or private to a particular tumor.
One property they often share with single-residue hot-
spots and previously functionally characterized muta-
tions is 3D proximity; i.e., rare mutations can be
physically close to each other or to a known and com-
mon mutation in the same protein, raising the possibility
that these mutations are also driver events. To prioritize
rare driver mutations for functional or clinical validation,
we developed a novel method that identifies significantly
mutated regions in 3D protein structures. We applied
this method to more than 11,000 tumors analyzed by
whole exome or genome sequencing.
Our analysis identified several thousand, mostly novel,
candidate functional cancer mutations. While some
mutations in the 3D clusters were in single-residue hot-
spots, which by definition are frequently mutated in can-
cer, the majority were rare mutations. Functional
annotation is often not available or sparse for these rare
mutations. On the one hand, rarely mutated residues
coupled to a single-residue hotspot often occur in many
well-studied oncogenes (such as KRAS, BRAF, EGFR,
PIK3CA, and MTOR, among many others) and in sev-
eral frequently mutated tumor suppressor genes (such as
TP53 and PTEN). It is plausible that the functional
impact of such mutations is similar to those in the
single-residue hotspots, and hence transfer of functional
annotation from the common mutations to the rare
mutations in the same 3D cluster makes sense. On the
other hand, the functional annotation of rarely mutated
residues, which are not coupled in a 3D cluster to a
single-residue hotspot but instead clustered only with
other rarely mutated residues, is much less certain.
Fortunately, the placement of the clusters of mutated
residues in known 3D structures affords the opportunity
for informative mechanistic hypotheses facilitating the
design of focused functional studies. For example, we
identified a cluster of mutations that likely disrupt crit-
ical calcium-binding sites in CDH1, a tumor suppressor
that mediates cell adhesion. Another example is a cluster
of mutations in KEAP1 that potentially disrupt binding
sites with NRF2, a key regulator of the cellular oxidative
response.
By experimentally validating candidate functional mu-
tations in 3D clusters in MAP2K1 and RAC1, we show
that our method readily identifies previously occult rare
activating mutations that could not be revealed by pos-
itional frequency analyses alone and that a subset of
such mutations are potential biomarkers of sensitivity to
targeted inhibitors in individual patients with cancer.
We showed, for example, that the rare MAP2K1 G128D
and Y130C mutations induce MAPK pathway activation
and that such mutations retain sensitivity to MEK in-
hibitor treatment in vitro. While some mutations identi-
fied by our analysis were not activating in vitro, such as
MAP2K1 mutations of A52, by analyzing mutations in
the context of protein structures, we can form hypoth-
eses about the biochemical reasons for such results: in
this case, A52 does not interact strongly with the kinase
domain in the wild-type 3D structure (Fig. 4b). This ex-
ample illustrates the potential functional insights
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resulting from detailed analysis of individual cancer
mutations in the context of 3D structures.
A proportion of rare mutations are not only biologic-
ally interesting (since they potentially promote tumor
initiation or progression), but also clinically important
with the advent of genomic-based clinical trial designs
(such as the NCI-Molecular Analysis for Therapy Choice
(NCI-MATCH) trial). Forty-five percent of the 11 K
tumor samples in our dataset lacked a single-residue
hotspot driver mutation, and identifying the genetic
drivers of these patients is a critical step for the choice
of therapy, design of clinical trials, or drug development.
Here, we achieved a partial advance in this direction by
identifying potential driver mutations in 17% of the sam-
ples without single-residue hotspot driver mutations (8%
of all samples). Some of the identified mutations, e.g.,
those in MTOR, EGFR, and MAP2K1, could have imme-
diate translational importance. For example, clinical tri-
als enrolling patients with MAPK pathway mutations,
e.g., the NCT01781429 trial, could expand their eligibil-
ity criteria beyond single-residue hotspot mutations in
the MAPK pathway and enroll patients with the
MAP2K1 3D cluster mutations identified here.
While our approach can identify novel and potentially
interesting mutations in cancer genes and in genes previ-
ously unknown to be involved in cancer, the method is
still limited by the lack of complete protein structure data
for many genes. For the 18,100 genes with mutations in
our dataset, we were able to align 7390 of them to one or
more protein structures. However, for many genes, the
structures included only individual protein domains, limit-
ing the scope of our analysis. There were only 1307 genes
with a protein structure that covered more than 90% of
the protein length, and only 3183 genes with more than
50% coverage. This limits the ability of our algorithm to
detect 3D clusters that were not close in sequence, for ex-
ample, those involved in domain-domain interactions.
Fortunately, as protein structure characterization tech-
nologies such as cryo-electron microscopy (cryo-EM)
advance, more protein structures, and more complete pro-
tein structures, are being generated. We can also make
use of the remarkable progress in 3D protein structure
prediction using evolutionary couplings for proteins that
are members of protein families with many known hom-
ologous sequences (http://evfold.org) [42, 43]. We thus
plan to periodically include new protein structures in our
analysis pipeline, which along with the inclusion of add-
itional sequencing data will allow for the nomination of
additional novel 3D clusters. Given the current coverage
of human proteins by 3D structural knowledge, one
can expect a steady increase in the number of candi-
date functional mutations identified by methods of
this type as more accurate structures of most human
proteins become available.
Like any statistical method, the power of our ap-
proach is also limited by the number of available
tumor samples. For example, a 3D cluster in AKT1
(R15, E17, W22, and D323) did not score as statisti-
cally significant (p = 0.11) as a 3D cluster. There is no
issue with the fact that the cluster contains the most
frequent single-residue hotspot mutation E17K, which
has been evaluated as an indicator of response to
AKT-targeted inhibitors in clinical trials [44]. But
D323 is not identified as a candidate by our method
on the current dataset, while experimental in vitro
studies indicate that AKT1 D323 mutations lead to
constitutive activation of AKT [45]. Fortunately, as
more cancer genomic data are generated, additional
significant 3D clusters will likely emerge.
We have shown that the mutational 3D clusters identi-
fied by three alternative methods (Mutation3D [17],
HotMAPS [18], and Hotspot3D [19]) and our method
are largely complementary (Additional file 7: Figure S2).
While different mutational and structural datasets used
by these four tools may have led to some of the differ-
ences observed, methodological differences likely domin-
ate. For example, unlike the other methods, HotMAPS
identified some single-residue hotspots as functional
without clustering them with other residues in 3D struc-
tures; e.g., IDH1 R132 was predicted by HotMAPS as
the only recurrently mutated residue in the gene.
Another methodological difference was the distance cut-
offs that were used to decide whether two residues are
interacting in 3D structures. For example, Hotspot3D
utilized interactions of longer distance (comparing to
other methods), e.g., IDH2 R172 was detected in a clus-
ter with R140 with a distance of 10 Å. Another reason
for differences in results from the different methods may
be due to differences in the sensitivity and specificity
levels. Mutation3D and HotMAPS used a high-
specificity and low-sensitivity cutoff and therefore pre-
dicted as functional only about 400 mutated residues in
less than 100 genes, most of which were single-residue
hotspots. Conversely, Hotspot3D nominated close to
15,000 mutated residues in almost 2500 genes (poten-
tially high sensitivity), which may include many false
positives (low specificity). An analysis of the results of a
pooled in vivo tumor formation assay and gene expres-
sion profile of numerous low frequency somatic genetic
variants by Kim et al. [20] supports this observation: All
mutations identified by Mutation3D and most mutations
identified by HotMAPS that were shown to be func-
tional in the screen were single-residue hotspots,
whereas our method and Hotspot3D were able to iden-
tify significantly more of the functional rare mutations.
Finally, the Hotspot3D prediction included a consider-
able number of false positives (false detection rate 32%
compared to 12% of our method when applied to the
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Kim et al. data) (Additional file 8: Table S6). As there is
no definitive comprehensive gold standard of mutations
with positive functional impact for the proliferation of
cancer cells, it is reasonable to take the top-ranked
results of any of the available methods as a point of
departure for functional genomics experiments, while
taking into consideration the qualitative differences
between the different methods.
Conclusions
In this work, we present a novel computational method
for identifying mutational 3D clusters of potential func-
tional significance with results based on the largest
whole exome or genome dataset analyzed in the context
of protein structures to date. We identified putative
driver mutations in more than 3000 protein residues,
the majority of which are rare mutations that have not
been identified by previous gene-, residue-, or cluster-
based methods of recurrence analysis. We experimen-
tally validated an activating role of a few rare mutations
in MAP2K1 and RAC1 as a proof of concept that com-
putational 3D structure analysis of mutations can gener-
ate useful hypotheses for functional and preclinical
validation.
By making regularly updated results available through
an interactive website (http://3dhotspots.org) as well as
via the widely used cBioPortal for Cancer Genomics, we
hope to facilitate future functional and clinical testing of
numerous candidate driver alterations, with increasing
accuracy as larger datasets become available. While
large-scale unbiased experimental screening has proven
to be successful in identifying novel functional mutations
in cancer [20], our results provide a way to prioritize
variants and have the potential to considerably increase
the efficiency of functional screening experiments. This
work has immediate translational significance, as it can
potentially be used directly to help guide clinical trial
enrollment of patients based on individual tumor
profiles.
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